S V Rajkumar
Overview
Explore the profile of S V Rajkumar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
172
Citations
7514
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Vaxman I, Kumar S, Buadi F, Lacy M, Dingli D, Hwa Y, et al.
Leukemia
. 2024 Jun;
38(8):1866.
PMID: 38886493
No abstract available.
2.
Vaxman I, Kumar S, Buadi F, Lacy M, Dingli D, Hayman S, et al.
Blood Cancer J
. 2023 May;
13(1):91.
PMID: 37253713
No abstract available.
3.
Vaxman I, Abeykoon J, Dispenzieri A, Kumar S, Buadi F, Lacy M, et al.
Blood Cancer J
. 2021 Dec;
11(12):196.
PMID: 34876555
Belantamab mafodotin is a highly selective targeted therapy for multiple myeloma. It targets the B cell maturation antigen (BCMA) on plasma cells and showed promising results in several randomized clinical...
4.
Visram A, Soof C, Rajkumar S, Kumar S, Bujarski S, Spektor T, et al.
Blood Cancer J
. 2021 Jun;
11(6):120.
PMID: 34168119
Soluble BCMA (sBCMA) levels are elevated in monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). However, the association between sBCMA levels and prognosis in MGUS and SMM...
5.
Vaxman I, Kumar S, Buadi F, Lacy M, Dingli D, Hwa Y, et al.
Leukemia
. 2021 May;
35(12):3604-3607.
PMID: 34021252
No abstract available.
6.
Dispenzieri A, Larson D, Rajkumar S, Kyle R, Kumar S, Kourelis T, et al.
Leukemia
. 2020 Jun;
34(10):2749-2753.
PMID: 32594098
Our group previously demonstrated that M-protein light chain (LC) glycosylation can be detected on routine MASS-FIX testing. Glycosylation is increased in patients with immunoglobulin LC amyloidosis (AL) and rarely changes...
7.
Landgren O, Graubard B, Kumar S, Kyle R, Katzmann J, Murata K, et al.
Blood Cancer J
. 2017 Oct;
7(10):e618.
PMID: 29053158
We studied the prevalence of monoclonal gammopathy of undetermined significance (MGUS) in younger individuals, age 10-49 years, using samples from the National Health and Nutritional Examination Survey (NHANES) III. NHANES...
8.
Sidana S, Tandon N, Dispenzieri A, Gertz M, Buadi F, Lacy M, et al.
Leukemia
. 2017 Sep;
32(3):729-735.
PMID: 28919633
Hematologic response criteria in light chain (AL) amyloidosis require the difference in involved and uninvolved free light chains (dFLC) to be at least 5 mg/dl. We describe the clinical presentation...
9.
Binder M, Rajkumar S, Ketterling R, Greipp P, Dispenzieri A, Lacy M, et al.
Blood Cancer J
. 2017 Sep;
7(9):e600.
PMID: 28862698
Fluorescence in situ hybridization evaluation is essential for initial risk stratification in multiple myeloma. While the presence of specific cytogenetic high-risk abnormalities (HRA) is known to confer a poor prognosis,...
10.
Ailawadhi S, Mikhael J, LaPlant B, Laumann K, Kumar S, Roy V, et al.
Leukemia
. 2017 Sep;
32(3):719-728.
PMID: 28860655
Despite therapeutic advances, multiple myeloma remains incurable, with limited options for patients with refractory disease. We conducted a large, multi-cohort clinical trial testing various doses and treatment schedules of pomalidomide...